Zymib 3,5 mg Powder for solution for injection

Indication

Treatment of multiple myeloma and relapsed mantle cell lymphoma.

Dosage (summary)

1.3 mg/mu00b2 twice weekly for 2 weeks, followed by a 10-day rest; adjust for toxicity.

Special Populations

• Elderly
• Renal impairment
• Hepatic impairment

Pregnancy & Breastfeeding

Not established; avoid breastfeeding during treatment.

Key Drug Interactions

• CYP3A4 inhibitors
• CYP3A4 inducers

Contraindications

• Hypersensitivity to bortezomib
• Acute diffuse infiltrative pulmonary disease

Common side effects

• Nausea
• Diarrhoea
• Fatigue
• Thrombocytopenia
• Peripheral neuropathy

Counselling Points

• Use effective contraception
• Monitor for signs of neuropathy
• Report any severe side effects